Outperform was Maintained on Natera (NASDAQ:NTRA) by Baird; with $20 Target.

June 29, 2018 - By Jimmy Cauthen

Natera, Inc. (NASDAQ:NTRA) Corporate Logo

Reiterated Natera (NASDAQ:NTRA) Rating.

Natera (NASDAQ:NTRA)‘s stock Outperform rating was reconfirmed by Analysts at Baird on Thursday, 28 June. The broker’s Equity research analysts have a $20 price target and would suggest a potential upside of 4.22 % on the stock.

Natera, Inc. (NASDAQ:NTRA) Ratings Coverage

Total analysts of 4 have positions in Natera (NASDAQ:NTRA) as follows: 4 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since March 14, 2018 according to StockzIntelligence Inc Natera has 8 analyst reports. On Friday, June 22 the rating was maintained by Craig Hallum with “Buy”. The stock rating was maintained by Morgan Stanley with “Overweight” on Wednesday, May 9. On Thursday, June 28 Robert W. Baird maintained Natera, Inc. (NASDAQ:NTRA) with “Outperform” rating. In Wednesday, March 14 report Robert W. Baird maintained it with “Buy” rating and $17.0 target. On Wednesday, March 14 the firm earned “Buy” rating by Canaccord Genuity. The company rating was maintained by Canaccord Genuity on Monday, June 25. In Monday, June 25 report Morgan Stanley maintained the stock with “Overweight” rating.

The stock increased 1.16% or $0.22 during the last trading session, reaching $19.19.Currently Natera, Inc. is uptrending after 12.60% change in last June 29, 2017. NTRA has 209,466 shares volume. NTRA outperformed the S&P500 by 0.03%.

Natera, Inc. (NASDAQ:NTRA)’s earnings report is expected on August, 14., according to Zacks. The EPS diference is $0.01 or 1.92 % down from last years number. Previous year: $-0.52; Analysts forcast: $-0.53. Wall Street now predicts -13.11 % EPS growth despite Natera, Inc. previous quarter’s EPS of $-0.61.

Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services.The firm is worth $1.05 billion. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.Last it reported negative earnings. The firm also provides Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father.

For more Natera, Inc. (NASDAQ:NTRA) news published briefly go to: Fool.com, Benzinga.com, Benzinga.com, Streetinsider.com or Benzinga.com. The titles are as follows: “Why Natera Inc. Is Rising Today” published on June 25, 2018, “44 Biggest Movers From Yesterday” on June 26, 2018, “42 Biggest Movers From Yesterday” with a publish date: June 28, 2018, “Natera (NTRA) Announces Powerful Kidney Transplant Rejection Biomarker” and the last “40 Stocks Moving In Wednesday’s Mid-Day Session” with publication date: June 27, 2018.

Natera, Inc. (NASDAQ:NTRA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.